Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B

Phase 3/4, single arm, open-label study to evaluate PK, safety, and efficacy of APVO101 prophylaxis in severe or moderately severe hemophilia B subjects < 12 years of age.

Study Overview

• Status: Completed
• Conditions: Hemophilia B
• Intervention / Treatment: Drug: APVO101

Detailed Description

Study APVO101-903 is a Phase 3/4, single arm, open-label clinical trial. The purpose of the study is to evaluate pharmacokinetics (PK), safety, and efficacy of APVO101 prophylaxis in severe or moderately severe hemophilia B subjects < 12 years of age. The study is designed to gather information in two age groups of previously treated (with a minimum of 50 previous ED to factor IX replacement therapy) pediatric patients, specifically those < 6 years of age and 6 to <12 years of age.

Study APVO101-903 consists of three distinct phases:

• PK Phase - PK evaluation will consist of administration of a single 75 ± 5 IU/kg dose, followed by factor IX activity and safety assessments up to 50 hours post-infusion.
• Treatment Phase - subjects will receive APVO101 prophylaxis (starting prophylaxis dose to be determined based on APVO101 recovery; ideally within the recommended dose range: 35 - 75 IU/kg; twice weekly) for 50 ED (approximately 6 months).
• Continuation Phase - subjects may continue to receive APVO101 prophylaxis (recommended dose range: 35 - 75 IU/kg; twice weekly) for an additional ≥ 50 ED.

• Study Type: Interventional
• Enrollment (Actual): 21
• Phase: Phase 3

Contacts and Locations

Study Locations

• Brazil
  • Campinas, Brazil, 13083-878
    • Universidade Estadual de Campinas - Centro de Hematologia e Hemoterapia
  • Ribeirão Preto, Brazil, 14051-140
    • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo
  • Espirito Santo
    • Vitória, Espirito Santo, Brazil, 29040-090
      • Centro Estadual de Hemopterapia e Hematologia do Espirito Santo
• Georgia
  • Tbilisi, Georgia, 0159
    • JSC K Eristavi National Center for Experimental and Clinical Surgery
• Moldova, Republic of
  • Chisinau, Moldova, Republic of, MD-2062
    • PMSI Institute of Mother and Child
• South Africa
  • Johannesburg, South Africa, 2193
    • Haemophilia Comprehensive Care Centre
  • Gauteng
    • Benoni, Gauteng, South Africa, 1500
      • Worthwhile Clinical Trials, Lakeview Hospital
• Turkey
  • Adana, Turkey, 01330
    • Cukurova University School of Medicine
  • İzmir, Turkey, 35100
    • Ege University School ofMedicine
• Ukraine
  • Kyiv, Ukraine, 01135
    • National Specialized Children's Hospital OKHMATDYT
  • Lviv, Ukraine, 79044
    • State Institute: Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 12 years (CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age: < 11.5 years of age at the time of the first dose and < 12 years throughout the Treatment Phase of the study (for at least 50 ED).
2. Informed consent: subject's parent or legal guardian written Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent. An assent form (IRB/EC-approved) will be obtained, when required by local regulations/guidelines.
3. Willingness and ability to make the required study visits, and follow instructions while enrolled in the study (for at least 50 ED; approximately 6 months).
4. Documented severe or moderately severe hemophilia B diagnosis (factor IX activity ≤ 2 IU/dL); in addition, severity may be indicated by the occurrence of one or more joint bleeding episode(s) at any point in the child's medical history requiring infusion(s) to replace factor IX.
5. Subjects must be on prophylaxis or switch to a prophylaxis regimen for the duration of the study.
6. Previously treated patients with a minimum of 50 ED (as documented and determined by the investigator) to a preparation/blood components containing factor IX.
7. Willingness to adhere to the 4-day washout period of any factor IX replacement therapy prior to PK evaluation. In case of previous exposure to a factor IX product with a prolonged half-life, a washout period of 3 half-lives is required in order to achieve steady state factor IX level prior to exposure to APVO101.
8. Immunocompetent (CD4 count > 400/mm3) and not receiving immune modulating or chemotherapeutic agents.
9. Platelet count at least 150,000/mm3.
10. Liver function: alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2 times the upper limit of the normal range.
11. Total bilirubin ≤ 1.5 times the upper limit of the normal range.
12. Renal function: serum creatinine ≤ 1.25 times the upper limit of the normal range.
13. Hemoglobin ≥ 7 g/dL.

Exclusion Criteria:

1. History of factor IX inhibitor ≥ 0.6 Bethesda Units (BU); confirmed by the screening result.
2. Existence of another coagulation disorder.
3. Evidence of thrombotic disease, fibrinolysis, or disseminated intravascular coagulation (DIC).
4. Use of an investigational drug within 30 days prior to study entry.
5. Previous use of APVO101.
6. Use of medications that could impact hemostasis, such as aspirin.
7. Known hypersensitivity to the active substance or to any of the excipients in the investigational products.
8. Known allergic reaction to hamster proteins.
9. History of poor compliance, geographic isolation, unreliable transportation, a serious medical or social condition, or any other circumstance that, in the opinion of the investigator, would interfere with participation or compliance with the study protocol.
10. History of adverse reaction to either plasma-derived factor IX or recombinant factor IX that interfered with the subject's ability to treat bleeding episodes with a factor IX product.
11. History of any medical condition that would impact the efficacy evaluation and/or safety evaluation of the study product.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: APVO101; APVO101: 35 - 75 IU/kg; twice weekly	Drug: APVO101; APVO101: 35 - 75 IU/kg; twice weekly; Other Names: IB1001; Recombinant factor IX; IXINITY

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Annualized Bleed Rate	Measure assessed during the Treatment Phase	6 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the plasma concentration curve from time 0 to t (AUC0-t)	Factor IX activity at the following time points post-infusion: 15-30 minutes, 4-6 hours, 24-26 hours and 46-50 hours	Pre-infusion to 50 hours following infusion
Terminal Half-life (t 1/2)	Factor IX activity at the following time points post-infusion: 15-30 minutes, 4-6 hours, 24-26 hours and 46-50 hours	Pre-infusion to 50 hours following infusion
Maximum post-infusion plasma concentration (Cmax)	Factor IX activity at the following time points post-infusion: 15-30 minutes, 4-6 hours, 24-26 hours and 46-50 hours	Pre-infusion to 50 hours following infusion
Incremental Recovery	Factor IX activity at the following time points post-infusion: 15-30 minutes, 4-6 hours, 24-26 hours and 46-50 hours	Pre-infusion to 50 hours following infusion
Clearance (CL)	Factor IX activity at the following time points post-infusion: 15-30 minutes, 4-6 hours, 24-26 hours and 46-50 hours	Pre-infusion to 50 hours following infusion
Volume of Distribution at steady-state (V dss)	Factor IX activity at the following time points post-infusion: 15-30 minutes, 4-6 hours, 24-26 hours and 46-50 hours	Pre-infusion to 50 hours following infusion
Degree of Hemorrhage Control	Subjects rating of bleed control within 6 hours of the time bleeding has stopped: Excellent: a dramatic response with abrupt pain relief and clear reduction in joint or hemorrhage site size; Good: pain relief or reduction in hemorrhage site size that may have required an additional infusion for resolution; Fair: probable or slight beneficial response usually requiring one of more additional infusions for resolution; Poor: no improvement or condition worsens.	6 Months

Collaborators and Investigators

• Sponsor: Medexus Pharma, Inc.
• Investigators: Study Chair: Khaled Mohamed, Medexus Pharma, Inc.

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 16, 2020
• Primary Completion (ACTUAL): July 4, 2022
• Study Completion (ACTUAL): July 4, 2022

Study Registration Dates

• First Submitted: February 25, 2019
• First Submitted That Met QC Criteria: February 25, 2019
• First Posted (ACTUAL): February 26, 2019

Study Record Updates

• Last Update Posted (ACTUAL): August 31, 2022
• Last Update Submitted That Met QC Criteria: August 26, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Hematologic Diseases; Blood Coagulation Disorders, Inherited; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Blood Coagulation Disorders; Hemophilia A; Hemophilia B
• Other Study ID Numbers: APVO101-903

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No